Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Int J Mol Sci ; 23(2)2022 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-35054911

RESUMO

Hematuria is an essential symptom of immunoglobulin A nephropathy (IgAN). Although the etiology of hematuria in IgAN has not been fully elucidated, it is thought that the rupture of the glomerular basement membranes caused by intra-capillary leukocyte influx, so-called glomerular vasculitis, is the pathological condition responsible for severe hematuria. Glomerular vasculitis are active lesions that exist in the glomeruli of acute phase IgAN and it is important because it is suspected to make the transition to segmental glomerular sclerosis (SGS) as a repair scar lesion in the chronic phase, and the progression of SGS would eventually lead to glomerular obsolescence. Worsening of hematuria concomitant with acute pharyngitis is common in patients with IgAN; therefore, elucidating the relationship between the immune system of Waldeyer's ring, including the palatine tonsil and epipharyngeal lymphoid tissue, and the glomerular vasculitis may lead to understanding the nature of IgAN. The epipharynx is an immunologically activated site even under normal conditions, and enhanced activation of innate immunity is likely to occur in response to airborne infection. Hyperactivation of innate immunity via upregulation of Toll-like receptors in the interfollicular area of the palatine tonsil and epipharyngeal lymphoid tissue, followed by enhanced fractalkine/CX3CR1 interactions, appears to play an important role in the development of glomerular vasculitis in IgAN. As latent but significant epipharyngitis is present in most patients with IgAN, it is plausible that acute upper respiratory infection may contribute as a trigger for the innate epipharyngeal immune system, which is already upregulated in a chronically inflamed environment. Given that epipharyngitis and its effects on IgAN are not fully understood, we propose that the so-called "epipharynx-kidney axis" may provide an important focus for future research.


Assuntos
Suscetibilidade a Doenças , Glomerulonefrite por IGA/etiologia , Imunidade nas Mucosas , Linfócitos Intraepiteliais/imunologia , Glomérulos Renais/imunologia , Tonsila Palatina/imunologia , Animais , Biomarcadores , Terapia Combinada/métodos , Gerenciamento Clínico , Progressão da Doença , Glomerulonefrite por IGA/diagnóstico , Glomerulonefrite por IGA/metabolismo , Glomerulonefrite por IGA/terapia , Humanos , Imuno-Histoquímica , Linfócitos Intraepiteliais/metabolismo , Glomérulos Renais/patologia , Técnicas de Diagnóstico Molecular , Tonsila Palatina/metabolismo , Subpopulações de Linfócitos T/imunologia , Subpopulações de Linfócitos T/metabolismo
2.
CEN Case Rep ; 10(4): 598-602, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34138451

RESUMO

Renal cyst infection is a frequent and serious problem in patients with autosomal dominant polycystic kidney disease (ADPKD). Cyst infection is often a refractory complication of treatment that leads to sepsis and death in patients with ADPKD. It was previously reported that a higher dose of dialysis demonstrated clearly better survival than shorten-time dialysis. The relationship between the frequency of cyst infection episodes in hemodialysis (HD) patients with ADPKD and the dialysis dose has not yet been fully elucidated. In this report, we describe a case of an HD patient with ADPKD that was provided elongation of HD time from 4-h twice weekly HD to 8-h thrice weekly nocturnal HD. As a result, the frequency of cyst infection episodes decreased from 10.0 to 1.5 days a month. Our findings suggest that prolonged HD time might contribute to amelioration of refractory cyst infections in patients with ADPKD.


Assuntos
Infecções/terapia , Rim Policístico Autossômico Dominante/complicações , Diálise Renal , Humanos , Infecções/etiologia , Masculino , Pessoa de Meia-Idade
3.
Immunol Res ; 65(1): 66-71, 2017 02.
Artigo em Inglês | MEDLINE | ID: mdl-27592233

RESUMO

The epipharynx is an immunologically active site even under normal conditions, and enhanced immunologic activation is prone to occur in response to an upper respiratory infection, air pollution, and possibly to vaccine adjuvants. Due to the potential link between the central nervous system and immune function, a relationship between epipharyngitis and autonomic nervous disturbance as well as autoimmune disease has been suggested. Various functional somatic symptoms have been described after human papillomavirus (HPV) vaccination, although a causal relationship has not been established. We examined the epipharynx in young women showing functional somatic symptoms following HPV vaccination. Surprisingly, despite having minimal symptoms involving the pharynx, all patients were found to have severe epipharyngitis. In addition, significant improvement in symptoms was seen in most patients who underwent epipharyngeal treatment. Thus, we speculate that the chronic epipharyngitis potentially caused by the vaccine adjuvant may be involved in the pathogenesis of functional somatic syndrome (FSS) post-HPV vaccination. Further, we suggest that epipharyngeal treatment may be effective for various types of FSS regardless of the initial cause, as well as for some autoimmune diseases, and that this may be an important direction in future research.


Assuntos
Adjuvantes Imunológicos/efeitos adversos , Adjuvantes Farmacêuticos/efeitos adversos , Doenças Autoimunes/etiologia , Doenças Faríngeas/etiologia , Adolescente , Adulto , Doenças Autoimunes/patologia , Feminino , Humanos , Vacinas contra Papillomavirus/efeitos adversos , Doenças Faríngeas/patologia , Faringe/patologia , Síndrome , Vacinação/efeitos adversos , Adulto Jovem
4.
Hemodial Int ; 20 Suppl 1: S17-S24, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-27669544

RESUMO

Introduction Oxidative stress is one of the main mediators of progression of chronic kidney diseases (CKD). Nuclear factor E2-related factor 2 (Nrf2) is the transcription factor of antioxidant and detoxifying enzymes and related proteins which play an important role in cellular defense. Long-time hemodialysis (HD) therapy (8 hours) has been considered to be more beneficial compared to normal HD therapy (4 hours). We investigated oxidative response related to Nrf2 in peripheral blood mononuclear cells (PBMCs) of long-time HD and normal HD patients. Methods Eight adult long-time HD therapy patients (44.5 ± 3.0 years) and 10 normal HD therapy patients (68.1 ± 2.7 years) were enrolled. PBMCs were isolated and processed for expression of Nrf2 and its related genes by qRT-PCR. Plasma indoxyl sulfate, amino acids, and body constituents were measured. Findings Plasma indoxyl sulfate was significantly low after long-time HD therapy compare to that of normal HD therapy. Although, skeletal muscle mass, lean body mass, mineral and protein were significantly decreased 2 months in normal HD patients, those in long-time HD patients were significantly increased after 2 months. Almost of amino acids were significantly decreased after HD therapy in both HD therapies. Plasma amino acids were significantly low in long-time HD patients compared to normal HD patients. In PBMCs, the expression of Nrf2 was significantly decreased and hemooxygenase-1 expression was significantly increased in long-time HD compared to normal HD. Conclusion These observations indicate the beneficial effects of in long-time HD in improving oxidative stress in patients.

5.
CEN Case Rep ; 4(2): 228-232, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28509110

RESUMO

Juxtaglomerular apparatus (JGA) hyperplasia rarely happened in renal biopsy and has been controversial clinically, because synthesis and secretion of renin were susceptible to the effect of clinical condition and medication. Here we present the case of a 39-year-old who got JGA hyperplasia of IgA nephropathy (IgAN) after long-term inhibition of the renin-angiotensin system (RAS) with an angiotensin receptor blocker (ARB), and a direct renin inhibitor (DRI) in combination with a diuretic. He was diagnosed with IgAN in his first renal biopsy, and was treated with supra-maximal dosages of ARB, DRI and a diuretic. In the second biopsy, because of the massive proteinuria and occurrence of steroid-induced diabetes, it was revealed that the area and the number of JGA cells were strikingly increased in observed glomeruli. Immunohistopathologically, the both specimens were stained by human renin antibody. The hyperplastic JG cells contained a large amount of renin granules. Putative renin granules were observed in some interstitial cells adjacent to an afferent arteriole by electron microscopy. The increasing response of renin granules co-localized in prominent JGA hyperplasia should be worried while physicians treat hypertensive patients with potent RAS inhibitors and diuretics even though they have diabetes. This is the first report showing a clinical course of forming prominent JGA hyperplasia directly after a full combination of RAS inhibitors and diuretics in adult IgA nephropathy.

7.
Clin Exp Nephrol ; 18(5): 770-7, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24477513

RESUMO

BACKGROUND: The primary abnormal manifestation in immunoglobulin A nephropathy (IgAN) is recurring bouts of hematuria with or without proteinuria. Although immunohistochemical analysis of renal biopsy tissue remains the gold standard not only for diagnosis but also for evaluating the activity of IgAN, new sensitive and reasonably specific noninvasive tests are emerging to guide therapeutic strategy applicable to all stages of IgAN. The present study examined serum levels of galactose-deficient IgA1 (Gd-IgA1) and its immune complex (IgA/IgG-IC) as noninvasive markers for the disease activity. METHODS: We enrolled 50 IgAN patients (male 40 %, median age 37 years) showing complete or partial clinical remission after steroid pulse therapy with tonsillectomy (TSP) whose clinical data and serum could be followed up for 3-5 years. RESULTS: Cross-sectional analysis revealed that the degree of hematuria and proteinuria were significantly associated with levels of Gd-IgA1 and levels of IgA/IgG-IC. Longitudinal analysis further showed that from the group of 44 patients with heavy hematuria before TSP, 31 patients showed complete disappearance of hematuria (group A), but the remaining patients did not (group B). Although the levels of Gd-IgA1 and IgA/IgG-IC in the two groups before TSP were similar, percentage decrease of Gd-IgA1 and IgA/IgG-IC levels in group A was significantly higher than in group B. CONCLUSION: Disease activity of IgAN assessed by hematuria and proteinuria correlated with serum levels and changes of Gd-IgA1 and IgA/IgG-IC. These new noninvasive disease activity markers can be useful for future activity scoring system and guiding therapeutic approaches.


Assuntos
Galactose/metabolismo , Glomerulonefrite por IGA/sangue , Imunoglobulina A/metabolismo , Adulto , Biomarcadores/sangue , Estudos Transversais , Feminino , Glomerulonefrite por IGA/terapia , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Tonsilectomia
8.
Clin Exp Nephrol ; 16(1): 122-9, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21912900

RESUMO

BACKGROUND: Because of the well-established annual urinalysis screening system in Japan, the duration of nephropathy (DN) can be estimated in more than half of all patients with IgA nephropathy (IgAN). Treatment using a combination of tonsillectomy and steroid pulse (TSP) therapy has been reported as an effective method for obtaining clinical remission (CR), defined as negative hematuria and proteinuria, in IgAN patients. The present study aims to identify the correlation between DN and CR rate in IgAN patients treated by TSP therapy. METHODS: We retrospectively investigated 830 IgAN patients who were followed up for 81.6 months after TSP therapy. DN could be estimated in 495 of the 830 patients. RESULTS: The CR rate among patients with DN ≤36 months was 87.3% (295/338 patients). The CR rate among patients with DN of 37-84 months was 73.3% (63/86 patients), while that among patients with DN ≥85 months was 42.3% (30/71 patients). The CR rate among the remaining 335 patients in whom DN could not be estimated because of missing annual urinalysis results was 43.6% (146/335 patients). A multivariate Cox regression model using data from the former group of 495 patients showed that DN ≤36 months was a significant predictor of CR (hazard ratio 1.839; 95% confidence interval 1.410-2.398; P < 0.001). CONCLUSION: Shorter DN is associated with higher likelihood of clinical remission in IgAN patients treated by TSP therapy.


Assuntos
Glomerulonefrite por IGA/tratamento farmacológico , Glomerulonefrite por IGA/cirurgia , Metilprednisolona/administração & dosagem , Prednisolona/administração & dosagem , Tonsilectomia , Adulto , Fatores Etários , Idoso de 80 Anos ou mais , Terapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Modelos de Riscos Proporcionais , Pulsoterapia , Indução de Remissão , Estudos Retrospectivos , Resultado do Tratamento
9.
Nephrology (Carlton) ; 15(1): 116-23, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20377779

RESUMO

AIM: The effectiveness of steroid pulse therapy combined with tonsillectomy (ST) has been shown in immunoglobulin A nephropathy (IgAN) patients with moderate or severe urinary abnormalities. The present study aimed to clarify whether the effectiveness may be extrapolated to IgAN with minor urinary abnormalities, and whether the effectiveness may depend on the histological severity with minor urinary abnormalities. METHODS: Data on 388 IgAN patients diagnosed by renal biopsies between 1987 and 2000 in Sendai Shakaihoken Hospital, who presented glomerular haematuria and minimal proteinuria (

Assuntos
Glomerulonefrite por IGA/complicações , Glomerulonefrite por IGA/terapia , Glucocorticoides/administração & dosagem , Hematúria/etiologia , Hematúria/terapia , Metilprednisolona/administração & dosagem , Prednisolona/administração & dosagem , Proteinúria/etiologia , Proteinúria/terapia , Tonsilectomia , Adolescente , Adulto , Idoso , Terapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Pulsoterapia , Indução de Remissão , Estudos Retrospectivos , Adulto Jovem
10.
Contrib Nephrol ; 157: 104-8, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-17495445

RESUMO

PURPOSE: In Japan, the annual urine health check-up system is well developed. Recently we reported a significant impact of tonsillectomy and steroid pulse therapy on clinical remission in our IgA nephropathy (IgAN) patients and indicated that clinical remission might terminate the progressive deterioration in renal function. We surveyed whether early detection of urinary abnormalities by annual urine health check-ups contribute to clinical remission in IgAN patients treated with tonsillectomy and steroid pulse therapy. METHODS: We investigated 380 IgAN patients in whom the onset year was identified by annual urine check-ups. Group A consisted of 264 patients in whom treatment intervention was initiated within 3 years after the first appearance of urinary abnormalities, and group B consisted of 116 patients who were diagnosed after more than 3 years duration of urinary abnormalities. We also classified our 380 patients by the degree of glomerular lesions; 233 patients with mild, 83 with moderate, and 64 with severe glomerular lesions. All patients were treated with tonsillectomy and steroid pulse therapy in our renal unit. RESULTS: The clinical remission rate of group A was 87.1%, while that of group B was 54.3%. In the mild glomerular lesion group, group B had a significantly lower remission rate than group A. Even in the severe glomerular lesion group, the remission rate of group A was significantly higher than that of group B. CONCLUSION: Our results indicate the annual health check-up system to be very useful for achieving clinical remission in IgAN patients, if they are treated with tonsillectomy and steroid pulse therapy.


Assuntos
Glomerulonefrite por IGA/diagnóstico , Glomerulonefrite por IGA/urina , Programas de Rastreamento , Urinálise , Adulto , Glomerulonefrite por IGA/tratamento farmacológico , Glomerulonefrite por IGA/cirurgia , Política de Saúde , Humanos , Japão , Pessoa de Meia-Idade , Pulsoterapia , Indução de Remissão , Esteroides/uso terapêutico , Tonsilectomia
11.
Am J Kidney Dis ; 41(1): 244-9, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12500244

RESUMO

Lipoprotein glomerulopathy (LPG), characterized by glomerular lipoprotein thrombi, presumably composed of abnormal apolipoprotein E (apoE), leads to a progressive decline in renal function and eventually results in end-stage renal failure. A successful treatment for LPG has not yet been established. The authors treated a 36-year-old woman with LPG and exhibiting a nephrotic syndrome using an intensive lipid-lowering therapy consisting of fenofibrate (300 mg), niceritrol (750 mg), ethyl-icosapentate (1,800 mg), and probucol (500 mg). After the start of treatment, a remarkable decrease in urinary protein excretion and improvement in the hyperlipidemia were obtained; proteinuria was no longer detected 11 months after the initiation of treatment. A second biopsy performed 11 months after the initiation of treatment showed the complete disappearance of the lipoprotein thrombi that had been observed in a diffuse and global manner in the first renal biopsy. These findings suggest that typical LPG could be regressed if the abnormal lipoproteinemia is controlled sufficiently.


Assuntos
Ácido Eicosapentaenoico/análogos & derivados , Hipolipemiantes/uso terapêutico , Nefropatias/diagnóstico , Nefropatias/tratamento farmacológico , Glomérulos Renais/efeitos dos fármacos , Glomérulos Renais/patologia , Lipídeos/sangue , Lipoproteínas/metabolismo , Adulto , Anticolesterolemiantes/uso terapêutico , Apolipoproteínas E/metabolismo , Combinação de Medicamentos , Ácido Eicosapentaenoico/uso terapêutico , Feminino , Fenofibrato/uso terapêutico , Humanos , Glomérulos Renais/ultraestrutura , Masculino , Microscopia Eletrônica , Síndrome Nefrótica/diagnóstico , Síndrome Nefrótica/tratamento farmacológico , Síndrome Nefrótica/genética , Niceritrol/uso terapêutico , Linhagem , Probucol/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA